Cooper CL - Search Results

1

Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?

Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A, Walmsley S, Klein M, Kelly D, Loutfy M, Thomas R, Sanche S, Kroch A, Machouf N, Roy-Gagnon MH, Hogg R, Cooper CL; Canadian Observational Cohort (CANOC) Collaboration. Rana U, et al. Among authors: cooper cl. BMC Infect Dis. 2019 Nov 21;19(1):982. doi: 10.1186/s12879-019-4617-8. BMC Infect Dis. 2019. PMID: 31752729 Free PMC article.

2

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.

Cooper CL, Parbhakar MA, Angel JB. Cooper CL, et al. Clin Infect Dis. 2002 May 1;34(9):1259-63. doi: 10.1086/339867. Epub 2002 Mar 28. Clin Infect Dis. 2002. PMID: 11941553

3

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.

Cooper CL, Cameron DW. Cooper CL, et al. Clin Infect Dis. 2002 Oct 1;35(7):873-9. doi: 10.1086/342388. Epub 2002 Sep 11. Clin Infect Dis. 2002. PMID: 12228825 Review.

4

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. Cooper CL, et al. AIDS. 2005 Sep 23;19(14):1473-9. doi: 10.1097/01.aids.0000183514.37513.d2. AIDS. 2005. PMID: 16135900 Clinical Trial.

5

Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV.

Cooper CL, Cameron DW. Cooper CL, et al. Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S105-9. doi: 10.1086/429506. Clin Infect Dis. 2005. PMID: 16265607

6

Therapeutic interventions for HIV infection and chronic viral hepatitis.

Cooper CL. Cooper CL. Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S69-72. doi: 10.1086/429499. Clin Infect Dis. 2005. PMID: 16265617 Review.

7

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia.

Cooper CL, Al-Bedwawi S, Lee C, Garber G. Cooper CL, et al. Clin Infect Dis. 2006 Jun 15;42(12):1674-8. doi: 10.1086/504386. Epub 2006 May 10. Clin Infect Dis. 2006. PMID: 16705570

8

Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.

Cooper CL, Mills E, Angel JB. Cooper CL, et al. AIDS. 2007 Jan 2;21(1):71-6. doi: 10.1097/QAD.0b013e3280110ada. AIDS. 2007. PMID: 17148970

9

Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia.

Cooper CL, Al-Bedwawi S. Cooper CL, et al. HIV Clin Trials. 2006 Sep-Oct;7(5):251-4. doi: 10.1310/hct0705-251. HIV Clin Trials. 2006. PMID: 17162319 Clinical Trial.

10

Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.

Cooper CL, Mills E. Cooper CL, et al. Int J STD AIDS. 2007 Aug;18(8):546-50. doi: 10.1258/095646207781439838. Int J STD AIDS. 2007. PMID: 17686217

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

446 results

Search Page

Filters